Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study – Reuters

Written by

admin

in

  1. Novo Nordisk’s Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study  Reuters
  2. Weight loss drugs can halve heart patients’ risk of early death, study finds  The Guardian
  3. Wegovy’s Cardiovascular Edge: Why Novo Nordisk is Outpacing Peers in the GLP-1 Space  AInvest
  4. Wegovy injection reduces heart attacks and stroke risks  The Jerusalem Post
  5. Weight loss jabs could keep heart failure patients out of hospital  Yahoo News New Zealand

Continue Reading

More posts